JAK2 and hematologic disorder: Targeted therapies that inhibit JAK-STAT signaling, such as JAK2 inhibitors (e.g., ruxolitinib and fedratinib), have shown efficacy in adult hematologic malignancies and are being explored in pediatric settings.